HUTCHMED (China) (HCM) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
HUTCHMED (China) (HCM) has outperformed Arcus Biosciences (RCUS) over the past year, losing 5.6% versus a loss of 29.2%. Over five years, HCM leads with a -62.4% price change compared with -66.3% for RCUS. HUTCHMED (China) is the larger company by market cap ($2.30 billion vs $2.25 billion), about 1.0 times the size, while Arcus Biosciences is growing revenue faster (-4.3% vs -13.0%).
HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -142.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | RCUS |
|---|---|---|
| Share price | $13.22 | $15.62 |
| Market cap | $2.30B | $2.25B |
| 1-day change | -1.71% | -1.01% |
| YTD return | -0.83% | -34.45% |
| 1-year return | -5.57% | -29.16% |
| 5-year return | -62.42% | -66.31% |
| P/E ratio (TTM) | 132.20 | — |
| Forward P/E | 51.00 | — |
| EPS (TTM) | $0.10 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $247.00M |
| Revenue growth (YoY) | -12.96% | -4.26% |
| Net income (latest FY) | $456.91M | $-353.00M |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | -156.28% |
| Net margin | 83.30% | -142.91% |
| 52-week high | $16.33 | $31.74 |
| 52-week low | $9.77 | $15.56 |
| Distance from 52-week high | -19.04% | -50.78% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +59.91% | +162.48% |
| Average volume | 64.48K | 1.85M |
| Shares outstanding | 173.81M | 143.99M |
| Employees | 1,790 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HCM has outperformed RCUS by 23.6 percentage points over the past year.
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
- Arcus Biosciences grew revenue faster in its latest fiscal year (-4.26% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
HCM vs RCUS FAQ
Which is bigger, HUTCHMED (China) or Arcus Biosciences?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.30B compared with $2.25B for Arcus Biosciences (RCUS).
Which stock has performed better over the past year, HCM or RCUS?
HCM returned -5.57% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.